Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
Volume 27
Issue 20
eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease
A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.
A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.
This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
This commentary highlights limitations of traditional access metrics and proposes incorporating eConsults to better capture specialty capacity, workload, and performance in modern health care delivery.